Linked Life Data

21515757

Source:http://linkedlifedata.com/resource/pubmed/id/21515757

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:21515757rdf:typepubmed:Citationlld:pubmed
pubmed-article:21515757lifeskim:mentionsumls-concept:C2349001lld:lifeskim
pubmed-article:21515757lifeskim:mentionsumls-concept:C0681850lld:lifeskim
pubmed-article:21515757lifeskim:mentionsumls-concept:C1706203lld:lifeskim
pubmed-article:21515757lifeskim:mentionsumls-concept:C2697811lld:lifeskim
pubmed-article:21515757lifeskim:mentionsumls-concept:C0132326lld:lifeskim
pubmed-article:21515757lifeskim:mentionsumls-concept:C0384228lld:lifeskim
pubmed-article:21515757lifeskim:mentionsumls-concept:C0596545lld:lifeskim
pubmed-article:21515757lifeskim:mentionsumls-concept:C0909839lld:lifeskim
pubmed-article:21515757lifeskim:mentionsumls-concept:C1550501lld:lifeskim
pubmed-article:21515757lifeskim:mentionsumls-concept:C0040808lld:lifeskim
pubmed-article:21515757lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:21515757lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:21515757pubmed:issue4lld:pubmed
pubmed-article:21515757pubmed:dateCreated2011-4-25lld:pubmed
pubmed-article:21515757pubmed:abstractTextWe retrospectively evaluated the durability and reasons for discontinuation of nevirapine (NVP) in combination with a tenofovir (TDF) and emtricitabine (FTC) or lamivudine (3TC)-containing antiretroviral therapy (ART) regimen in an Australian outpatient setting. Between January 2003 and June 2009, 64 patients (29 naïve and 35 treatment-experienced) received NVP/TDF-based regimens. The median exposure was 13.0 months (interquartile range [IQR] 6.0-20.0 months). The two- and three-year probability of continuing a NVP/TDF with FTC or 3TC regimen was 76% and 70%, respectively. Thirteen (20.3%) patients discontinued their regimen during the observation period. Reasons for discontinuation included virological failure in four (6.3%), rash in three (4.7%), lost to follow-up in three (4.7%), liver toxicity in two (3.1%) and HIV-1-related encephalopathy in one (1.6%). Long-term follow-up with a NVP/TDF-based regimen showed a low rate of discontinuation and enabled physicians to extend the use of ART over a long period, often with simplified (once-daily) regimens.lld:pubmed
pubmed-article:21515757pubmed:languageenglld:pubmed
pubmed-article:21515757pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21515757pubmed:citationSubsetIMlld:pubmed
pubmed-article:21515757pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21515757pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21515757pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21515757pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21515757pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21515757pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21515757pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21515757pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21515757pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21515757pubmed:statusMEDLINElld:pubmed
pubmed-article:21515757pubmed:monthAprlld:pubmed
pubmed-article:21515757pubmed:issn1758-1052lld:pubmed
pubmed-article:21515757pubmed:authorpubmed-author:CharD FDFlld:pubmed
pubmed-article:21515757pubmed:authorpubmed-author:SmithD EDElld:pubmed
pubmed-article:21515757pubmed:authorpubmed-author:JeganathanSSlld:pubmed
pubmed-article:21515757pubmed:authorpubmed-author:MaruszakHHlld:pubmed
pubmed-article:21515757pubmed:issnTypeElectroniclld:pubmed
pubmed-article:21515757pubmed:volume22lld:pubmed
pubmed-article:21515757pubmed:ownerNLMlld:pubmed
pubmed-article:21515757pubmed:authorsCompleteYlld:pubmed
pubmed-article:21515757pubmed:pagination228-30lld:pubmed
pubmed-article:21515757pubmed:meshHeadingpubmed-meshheading:21515757...lld:pubmed
pubmed-article:21515757pubmed:meshHeadingpubmed-meshheading:21515757...lld:pubmed
pubmed-article:21515757pubmed:meshHeadingpubmed-meshheading:21515757...lld:pubmed
pubmed-article:21515757pubmed:meshHeadingpubmed-meshheading:21515757...lld:pubmed
pubmed-article:21515757pubmed:meshHeadingpubmed-meshheading:21515757...lld:pubmed
pubmed-article:21515757pubmed:meshHeadingpubmed-meshheading:21515757...lld:pubmed
pubmed-article:21515757pubmed:meshHeadingpubmed-meshheading:21515757...lld:pubmed
pubmed-article:21515757pubmed:meshHeadingpubmed-meshheading:21515757...lld:pubmed
pubmed-article:21515757pubmed:meshHeadingpubmed-meshheading:21515757...lld:pubmed
pubmed-article:21515757pubmed:meshHeadingpubmed-meshheading:21515757...lld:pubmed
pubmed-article:21515757pubmed:meshHeadingpubmed-meshheading:21515757...lld:pubmed
pubmed-article:21515757pubmed:meshHeadingpubmed-meshheading:21515757...lld:pubmed
pubmed-article:21515757pubmed:meshHeadingpubmed-meshheading:21515757...lld:pubmed
pubmed-article:21515757pubmed:meshHeadingpubmed-meshheading:21515757...lld:pubmed
pubmed-article:21515757pubmed:meshHeadingpubmed-meshheading:21515757...lld:pubmed
pubmed-article:21515757pubmed:meshHeadingpubmed-meshheading:21515757...lld:pubmed
pubmed-article:21515757pubmed:meshHeadingpubmed-meshheading:21515757...lld:pubmed
pubmed-article:21515757pubmed:meshHeadingpubmed-meshheading:21515757...lld:pubmed
pubmed-article:21515757pubmed:meshHeadingpubmed-meshheading:21515757...lld:pubmed
pubmed-article:21515757pubmed:year2011lld:pubmed
pubmed-article:21515757pubmed:articleTitleClinical experience with nevirapine combined with tenofovir plus emtricitabine or lamivudine-containing regimens in HIV-infected subjects.lld:pubmed
pubmed-article:21515757pubmed:affiliationAlbion Street Centre, Surry Hills, Australia. Don.Smith@sesiahs.health.nsw.gov.aulld:pubmed
pubmed-article:21515757pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:21515757pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed